Holen Sie sich die Stockscreener-App
9.1342
0.88%
0.0692
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - The Manila Times
BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits
BCRX Should I Buy - Intellectia AI
(BCRX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
C5 inhibitors disclosed in Biocryst patents - BioWorld News
BioCryst to Present at Upcoming Investor Conference - GlobeNewswire
BioCryst stock holds firm after a Q2 revenue beat - AD HOC NEWS
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset - Stocktwits
BioCryst Pharmaceuticals Inc. (BCRX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet - finance.yahoo.com
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
BioCryst gets Japan approval for HAE drug in young children By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals Announces Japan Approval of ORLADEYO for Pediatric HAE Prophylaxis - Quiver Quantitative
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan - The Manila Times
BioCryst gets Japan approval for HAE drug in young children - Investing.com
BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now? - Sahm
NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen - ChartMill
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
BioCryst (BCRX) Quarterly Figures: Reported EPS Tops Expectations in the Latest Reading; Price Reaction: The Share Price Adds 3.81% at the CloseEarnings Growth Analysis - Vinanet
BioCryst (BCRX) Financial Update: EPS Exceeds Its Estimate in Latest Trading; Post-Report - vinanet.vn
Rice Hall James & Associates LLC Takes $23.32 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
What is HC Wainwright's Forecast for BCRX Q3 Earnings? - MarketBeat
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals Stock Price Forecast. Should You Buy BCRX? - StockInvest.us
RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares - Stock Titan
Research Analysts Issue Forecasts for BCRX Q4 Earnings - MarketBeat
Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - MarketBeat
Biocryst Pharmaceuticals Inc. (BCRX) News, Articles, Events & Latest Updates - Stocktwits
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance
A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - MarketBeat
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options - Yahoo Finance
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside - DirectorsTalk Interviews
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
Weekly Recap: Q2 revenue jump, raised guidance and Astria R&D charge, shift - TradingView
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
BCRX SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus
BioCryst Pharmaceuticals, Inc. (BCRX) Options Chain - Yahoo! Finance Canada
State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing - Stock Titan
0.35%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):